Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sharp TherapeuticsTSXV:SHRX 14 Debt-to-EBITDA is -0.14 as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 14/100. Among 316 Biotechnology companies, Sharp Therapeutics ranks worse than 316455.38% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sharp Therapeutics's Debt-to-EBITDA or its related term are showing as below:
TSXV:SHRX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.57 Med: -0.44 Max: -0.21
Current: -0.21
During the past 3 years, the highest Debt-to-EBITDA Ratio of Sharp Therapeutics was -0.21. The lowest was -2.57. And the median was -0.44.
TSXV:SHRX's Debt-to-EBITDA is ranked worse than 100% of 316
companies
in the Biotechnology industry
Industry Median: 1.255
vs TSXV:SHRX: -0.21
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sharp Therapeutics Debt-to-EBITDA Related Terms
Sharp Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sharp Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:SHRX vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Sharp Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sharp Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sharp Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Sharp Therapeutics (TSXV:SHRX) has a Debt-to-EBITDA of -0.14 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sharp Therapeutics. According to the industry distribution chart, Sharp Therapeutics ranks #999999 out of 316 companies in the Biotechnology industry.
Is Sharp Therapeutics' Debt-to-EBITDA too high?
Sharp Therapeutics' current Debt-to-EBITDA is -0.14. Based on the distribution chart, Sharp Therapeutics ranks #999999 out of 316 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sharp Therapeutics ranks #999999 out of 316 companies for Debt-to-EBITDA. This places Sharp Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sharp Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sharp Therapeutics's current Debt-to-EBITDA is -0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Debt-to-EBITDA of -0.14. The current Debt-to-EBITDA is -0.14. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Debt-to-EBITDA is -0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score
Get the complete analysis for TSXV:SHRX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SHRX has been successfully added to your 
